Ryan Mee, CEO of Fulcrum Metals, reviews FY23 and progress on the Gold Tailings Hub in Canada. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,156.00
Bid: 12,124.00
Ask: 12,128.00
Change: -14.00 (-0.12%)
Spread: 4.00 (0.033%)
Open: 12,114.00
High: 12,258.00
Low: 12,114.00
Prev. Close: 12,170.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UK PM Johnson says rising European cases means holidays look difficult

Tue, 23rd Mar 2021 19:04

(Alliance News) - UK Prime Minister Boris Johnson said it was "too early to say" whether foreign holidays will be allowed but rising cases in Europe meant "things certainly look difficult for the time being".

The prime minister said he hoped to give more information about foreign travel on April 5, a week before the government's global travel task force is due to report.

"A lot of people do want to know about what's going to happen on the holiday front and I know there's a great deal of curiosity and interest," Johnson said at a No 10 press conference.

"All I can say is it's just too early to say and my advice is to everybody to wait for the global travel task force to report.

"We've heard already that there are other European countries where the disease is now rising so things certainly look difficult for the time being but we will be able to say more we hope in a few days' time, I certainly hope to say more by April 5."

Under the current road map for easing restrictions, the earliest date people in England could go on holiday abroad would be May 17.

A senior scientific adviser has suggested people should plan to holiday in the UK this summer.

Professor Neil Ferguson, whose modelling led to the first UK lockdown last March, said relaxing border measures too early risked the success of the UK's vaccination programme.

He said the risk from Europe is the arrival of new variants, or importing cases of the troubling South African variant from countries where cases were rising.

He told BBC Radio 4's World at One programme: "I should say we also have some of the South African variant here already and other variants which may be similar, which we're watching very carefully, so that is overall the major concern going forward and why we need to be vigilant, not just looking at Europe, and what's happening within our borders as well."

Prof Ferguson said the effectiveness of the AstraZeneca PLC and Pfizer Inc vaccines "might drop substantially, 60% or 50%" in the face of variants.

"And what that means is if we then allow transmission to resume which it is likely to do as we relax social distancing measures, we have that faint risk of being back in a situation where we have rising infections, rising hospitalisations with people who have been vaccinated," he said.

"And back to, in the worst case, where we were in January.

"So, the effectiveness, exactly how effective vaccines is, is very critical to how quickly we're able.. to relax measures."

Asked if he was therefore in favour of keeping borders closed, Prof Ferguson said: "I certainly am in favour of relaxing border measures at a slower rate than we relax controls within the country, and doing all we can to reduce the risk of importation of variants which might undermine our vaccination programme."

Asked what he wanted to see, he said that meant having finished "vaccinating everybody under 50, which will be late summer, and having vaccines in our stockpile which we know work very effectively against those variants".

"Conservatively and being risk averse at the moment, I think we should be planning on summer holidays in the UK, not overseas."

He said most people travelling to and from France at the moment on essential business or for commerce were exempt from quarantine and testing measures.

"I think we need to reconsider that, not the quarantine bit, but for instance introducing testing of everybody coming back, including those essential workers."

By David Hughes and Jane Kirby

source: PA

Copyright 2021 Alliance News Limited. All Rights Reserved.

More News
2 May 2024 10:04

AstraZeneca notes positive trial results for Calquence treatment

(Alliance News) - AstraZeneca PLC on Thursday said it observed positive high-level results in the Echo phase 3 trial of its Calquence treatment for previously untreated adult patients with mantle cell lymphoma.

Read more
2 May 2024 07:45

AstraZeneca reports positive results from blood cancer drug trial

(Sharecast News) - AstraZeneca has reported positive results from the use of its Calquence drug in a clinical trial to treat a rare type of blood cancer.

Read more
29 Apr 2024 22:52

J&J, Bristol Myers lose challenges to US drug price negotiation program

April 29 (Reuters) - A U.S. judge on Monday rejected a challenge by Bristol Myers Squibb and Johnson & Johnson to a law requiring them to negotiate the prices of their blockbuster blood clot prevention drugs with the U.S government's Medicare health insurance program or pay heavy penalties.

Read more
29 Apr 2024 10:02

LONDON BROKER RATINGS: Deutsche Bank likes Frasers; Barclays cuts JD

(Alliance News) - The following London-listed shares received analyst recommendations Monday morning and Friday:

Read more
29 Apr 2024 09:13

AstraZeneca makes progress with Truqap and Enhertu cancer treatments

(Alliance News) - AstraZeneca PLC on Monday said its Truqap drug has been recommended for approval in the EU to treat a form of breast cancer, while also noting trial results for its Enhertu offering.

Read more
29 Apr 2024 07:50

LONDON BRIEFING: Hipgnosis Songs Fund backs new Blackstone bid

(Alliance News) - London's FTSE 100 is called to open higher on Monday, with heady gains for US tech stocks on Friday brightening the mood in Europe and Asia at the start of the new week.

Read more
29 Apr 2024 07:24

AstraZeneca makes progress with two breast cancer treatments

(Sharecast News) - AstraZeneca issued favourable updates on two of its breast cancer treatments on Monday - 'Truqap', or capivasertib, and 'Enhertu', or trastuzumab deruxtecan - following encouraging results from respective phase three trials.

Read more
26 Apr 2024 09:33

LONDON BROKER RATINGS: Peel Hunt cuts ConvaTec to 'reduce'

(Alliance News) - The following London-listed shares received analyst recommendations Friday morning:

Read more
25 Apr 2024 16:57

LONDON MARKET CLOSE: FTSE 100 shakes off red-hot US inflation gauge

(Alliance News) - London's FTSE 100 outperformed on Thursday, enjoying a solid rise on largely well-received corporate earnings and a share price jump for miner Anglo American after it received a takeover bid from peer BHP.

Read more
25 Apr 2024 15:14

London close: Stocks finish mixed as US GDP growth slows

(Sharecast News) - London's stock markets finished with a mixed performance on Thursday, as investors digested a slower-than-expected GDP growth reading from the United States, while a slew of well-received earnings underpinned the top-flight index.

Read more
25 Apr 2024 11:50

LONDON MARKET MIDDAY: FTSE 100 hits high on offer for Anglo American

(Alliance News) - The FTSE 100 was outperforming European markets at midday on Thursday, with the index boosted to a record high thanks to takeover talks.

Read more
25 Apr 2024 10:33

AstraZeneca leaps after smashing first-quarter forecasts

Q1 revenue up 19% to $12.68 bln

*

Read more
25 Apr 2024 09:18

TOP NEWS: AstraZeneca upbeat as cancer drugs underpin sales growth

(Alliance News) - AstraZeneca PLC on Thursday hailed the potential of its drugs pipeline as it delivered impressive growth in sales and profit in the first quarter.

Read more
25 Apr 2024 09:12

LONDON MARKET OPEN: Anglo American jumps on takeover bid from BHP

(Alliance News) - Stock prices in London opened mixed on Thursday, as investors cautiously eye data on the health of the US economy.

Read more
25 Apr 2024 08:38

AstraZeneca blows past analysts' estimates for Q1

(Sharecast News) - AstraZeneca posted better-than-expected revenues and profit for the first quarter of 2024 with both the company and analysts highlighting its drug pipeline.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.